基础医学与临床 ›› 2016, Vol. 36 ›› Issue (10): 1450-1454.
• 短篇综述 • 上一篇 下一篇
张李迪,刘珍,姜斌,高丰厚
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
基金资助:
Received:
Revised:
Online:
Published:
摘要： NVP-BEZ235是ATP竞争性的PI3K/mTOR双靶点抑制剂，可以通过周期阻滞和凋亡诱导作用在体外水平有效抑制肿瘤细胞的增殖。然而，临床前动物实验发现NVP-BEZ235单药治疗的抗肿瘤效果并不理想。但是，NVP-BEZ235与多种抗肿瘤药物联合应用时可以产生强大的协同效应，以NVP-BEZ235为基础的联合化疗方案可能成为肿瘤治疗的新策略。
关键词: NVP-BEZ235, 自噬, 凋亡, 联合化疗, 肿瘤
Abstract: NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, has exhibited significant anti-proliferative activity in a great variety of cancer types in vitro by inducing cell-cycle arrest and apoptosis. Disappointingly, NVP-BEZ235 monotherapy have not yielded satisfactory results in preclinical models. However, compared with every single agent alone, improved anti-tumor activity can often be achieved when NVP-BEZ235 combined with other cancer therapeutics. In this regard, NVP-BEZ235 in combination with chemotherapeutic drugs may present a new therapeutic strategy.
Key words: NVP-BEZ235, Autophagy, Apoptosis, Combination chemotherapy, Neoplasms
张李迪 刘珍 姜斌 高丰厚. NVP-BEZ235联合用药抗肿瘤的研究进展[J]. 基础医学与临床, 2016, 36(10): 1450-1454.
0 / / 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2016/V36/I10/1450
